好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

好色先生al Attainment Does Not Impact Longitudinal Processing Speed Test Performance in Multiple Sclerosis
Multiple Sclerosis
MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)
024

To determine the impact of education on PST performance at baseline and longitudinally.

The Processing Speed Test (PST) is an electronic implementation of the symbol digit modalities test. The PST is longitudinally administered to a multi-institutional multiple sclerosis (MS) population as part of MS PATHS (Partners Advancing Technology and Health Solutions), sponsored by Biogen.

MS PATHS data cut 11 (March 2020) was used. Inclusion required a diagnosis of clinically isolated syndrome or MS, ≥1 PST evaluation, and education data. Participants with repeat evaluations at 1 (6-18 months), 2 (18-30 months), and 3 years (30-42 months) were identified. Repeat assessments were classified as worsened (≥4 point drop), improved (≥4 point increase), or stable. 好色先生al attainment was classified as no diploma (<12 years), high school diploma (12-15 years), college degree (16-17 years), and graduate degree (≥18 years). Linear regression was used to determine the relationship between education and baseline PST performance. Logistic regression was used to determine the relationship between education and the likelihood of PST worsening. Models were adjusted for age, sex, MS phenotype, and disease duration.
The baseline analysis (n=11,757) showed a significant relationship between more education and better PST performance. For instance, individuals with a graduate degree averaged 10.5 more correct answers than those without a high school diploma (p<0.0001). At one year (n=6,264), graduate degree holders were 41% less likely to have a worsened PST than those with a high school diploma (p=0.011), but there were no other significant differences based on education. At two (n=2,369) and three (n=753) years, education did not significantly influence PST performance. Increasing age and primary progressive phenotype were significant predictors of worsened PST performance in most models.

Higher educational attainment is associated with better baseline PST performance but does not influence longitudinal stability of processing speed.
Authors/Disclosures
Devon Conway, MD
PRESENTER 		Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Conway has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Conway has received research support from Novartis. The institution of Dr. Conway has received research support from BMS. The institution of Dr. Conway has received research support from Biogen.
Sarah M. Planchon Pope, PhD, CCRP (Cleveland Clinic) Dr. Planchon Pope has nothing to disclose.
Robert A. Bermel, MD, FAAN (Cleveland Clinic) Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi/Genzyme. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Bermel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Bermel has received research support from Biogen. The institution of Dr. Bermel has received research support from Roche. The institution of Dr. Bermel has received research support from Novartis. Dr. Bermel has received intellectual property interests from a discovery or technology relating to health care.